Buy Qinlock from Insulinhub. Product of Europe.
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufacturer
Deciphera Pharmaceuticals (Netherlands) B.V.
Atrium Building 4th Floor
Strawinskylaan 3051
1077ZX, Amsterdam
Netherlands
Information about Qinlock (Ripretinib)
Qinlock (Ripretinib) is an oral targeted therapy used primarily to treat gastrointestinal stromal tumors (GISTs) that are resistant or intolerant to other treatments. It is a kinase inhibitor that works by blocking certain proteins (kinases) involved in the growth and survival of cancer cells. Qinlock is designed to target specific mutations in cancer cells, offering a more targeted approach to treatment for patients with advanced GIST.
Product Highlights
- Specifically for adult patients with GIST who have received prior treatment with other tyrosine kinase inhibitors (TKIs) and whose tumors are resistant or intolerant to those treatments.
Key Ingredient
Key Benefits
- Qinlock targets specific mutations and pathways involved in the growth of GIST, offering a more precise treatment approach compared to traditional chemotherapy.
- It is especially beneficial for patients with GISTs that have become resistant to other treatments, providing an option when other therapies have failed.
- Qinlock is taken as an oral tablet, providing convenience for patients compared to intravenous treatments.
- Clinical studies have shown that Qinlock can extend progression-free survival in patients with advanced GIST.
Direction of Use
- Qinlock is typically taken as a 150 mg oral tablet, once daily.
- It can be taken with or without food, ideally at the same time each day for consistency.
- The tablet should be taken whole with water and should not be chewed or crushed.
- The dosage may be adjusted based on tolerability or side effects.
- Treatment is usually continued until disease progression or unacceptable toxicity occurs.
Safety Concerns
- Common side effects may include nausea, diarrhea, and abdominal discomfort. Patients should be monitored for these issues.
- Some patients experience fatigue, which may affect daily activities.
- Ripretinib may cause an increase in blood pressure, which should be regularly monitored during treatment.
- Liver function tests should be performed periodically to monitor for any signs of liver damage.
- Qinlock may increase the risk of bleeding, particularly in patients who have other medical conditions or are on anticoagulant therapy.
- Ripretinib has been associated with heart-related issues, so patients with pre-existing heart conditions should be carefully monitored.
Avoid Qinlock (Ripretinib) If
- Patients with a known hypersensitivity to ripretinib or any other component of Qinlock should avoid taking the medication.
- Qinlock should be avoided in patients with severe liver dysfunction due to the risk of exacerbating liver damage.
- Patients with active bleeding disorders or those at high risk for bleeding should not use Qinlock, as it can increase bleeding risks.
- Qinlock is classified as a Category D medication during pregnancy, indicating a potential risk to the fetus. It should be avoided during pregnancy unless absolutely required.
- Ripretinib should be avoided during breastfeeding, as it is not known whether it passes into breast milk and could harm the infant.
